Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-07832837 · 1 trial · 2 indications
An adverse event (AE) was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect or other important medical events. An AE was considered as treatment emergent if the event started during the effective duration of treatment. All events that started on or after the first dosing day up to the last dose plus the lag time were considered as TEAEs.
Number of participants with any laboratory test abnormalities meeting pre-defined criteria was reported in this outcome measure.
Twelve lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, corrected QT (QTc) intervals and QRS complex. Clinically significant findings were determined by the investigator.
Vital signs included blood pressure, pulse rate, respiratory rate, oxygen saturation and oral temperature. Clinically significant findings were determined by the investigator.
Cardiac telemetry was collected in Part 1 SAD cohorts only. Number of participants with any cardiac telemetry abnormalities were reported in this outcome measure.
An adverse event (AE) was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect or other important medical events. An AE was considered as treatment emergent if the event started during the effective duration of treatment. All events that started on or after the first dosing day up to the last dose plus the lag time were considered as TEAEs.
Number of participants with any laboratory test abnormalities meeting pre-defined criteria was reported in this outcome measure.
Twelve lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, corrected QT (QTc) intervals and QRS complex. Clinically significant findings were determined by the investigator.
An adverse event (AE) was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect or other important medical events. An AE was considered as treatment emergent if the event started during the effective duration of treatment. All events that started on or after the first dosing day up to the last dose plus the lag time were considered as TEAEs.
Number of participants with any laboratory test abnormalities meeting pre-defined criteria was reported in this outcome measure.
Vital signs included blood pressure, pulse rate, respiratory rate, oxygen saturation and oral temperature. Clinically significant findings were determined by the investigator.
| Arm | Type | Description |
|---|---|---|
| PF-07832837 | EXPERIMENTAL | single or multiple doses of PF-07832837 at ascending dose levels |
| placebo | PLACEBO_COMPARATOR | single or multiple doses of placebo |
| Name | Type | Description |
|---|---|---|
| PF-07832837 | DRUG | escalated doses of PF-07832837 |
| Placebo | OTHER | placebo |
Inclusion Criteria: * Part 1 only: Adult participants between 18 to 55 years of age, inclusive, at the time of signing the ICD * Part 2 only: Adult participants, who at the time of screening, are between the ages of 18 and 70 years, inclusive. * Part 1 only: Participants who are overtly healthy as ...
Top 20 of 26 competitors
PF-07832837 is an investigational small molecule being studied for the treatment of atopic dermatitis, a chronic inflammatory skin condition. It is also being evaluated in healthy adult participants as part of its early clinical development. The drug has not been approved for any indication and remains in Phase 1 testing.
PF-07832837 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is the sponsor of the clinical program evaluating the compound in atopic dermatitis and in healthy volunteers.
PF-07832837 is in Phase 1 clinical development. The program consists of a single first-in-human study that is currently recruiting participants. No Phase 2 or later-stage trials have been initiated, and the drug is not approved for any use.
PF-07832837 is being evaluated in one clinical trial, NCT06564389, titled a first-in-human study to evaluate the tolerability of PF-07832837 in healthy adults and patients. The trial is recruiting, is placebo-controlled and double-blind, and plans to enroll 119 participants in the United States.
No, PF-07832837 is not FDA approved. It is an investigational small molecule in Phase 1 clinical development for atopic dermatitis. The only active study is a first-in-human trial assessing tolerability in healthy adults and patients, and it is currently recruiting participants.